Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nordic 8: Cetuximab + Alternating FOLFIRI/FOLFOX in mCRC
NCT01867697Phase 2Completed
- Sponsor
- Pfeiffer Pharmaceuticals
- Start
- May 2012
- Primary completion
- Mar 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of cetuximab in metastatic colorectal cancer (mCRC), sponsored by Pfeiffer Pharmaceuticals. Started May 2012; status: completed.
02
Drugs
cetuximab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT01867697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01867697.